The coffee on my desk has gone cold—a familiar state of affairs in this office—but the news cycle regarding Zynex, Inc. (ZYXIQ) remains anything but stagnant. Faruqi & Faruqi, LLP is turning up the pressure, reminding investors that April 21, 2026, is the hard deadline to step forward as a lead plaintiff in the federal securities class action currently targeting the medical device maker.
It’s a messy situation. The allegations, laid out in court filings, paint a picture of a company prioritizing aggressive sales over basic compliance. We’re talking about shipments of electrodes that weren’t actually needed, which supposedly inflated revenue numbers, and a rather messy entanglement with insurers like Tricare. It’s the kind of corporate behavior that makes you wonder how long they thought they could get away with it.
Actually, wait—let’s look at the timeline again. The trouble wasn’t just internal incompetence; the complaint points to a 2023 lawsuit from Travelers alleging a $23 million overbilling scheme. It feels like the writing was on the wall for a long time, but the markets often have a way of ignoring these things until they can’t. Or maybe investors just didn’t want to see it? Regardless, the fallout hit hard in March 2025 when Tricare suspended payments.
That March announcement wiped out more than half of the stock’s value in a single day—a 51.3% drop. When the company finally admitted to compliance failures later that July and announced the exit of key executives like Sandgaard and Moorhead, the stock cratered again, falling another 45%. It’s a classic, brutal cycle of disclosure and decline.
If you held Zynex shares between February 2021 and December 2025, Faruqi & Faruqi is asking for your attention. Josh Wilson, a partner at the firm, is taking direct calls. Whether you want to lead the charge as a plaintiff or just sit back as an absent member of the class, the clock is ticking.
It’s not just about the money, though that’s the main driver. Misryoum has seen enough of these cases to know that the discovery phase usually unearths even more headaches. The firm is also looking for whistleblowers—former employees or anyone with a story to tell about what was happening behind the scenes.
So, if you’re still holding the bag on ZYXIQ, you might want to reach out to them. Or don’t. Sometimes doing nothing is a choice, though I’m not sure that’s the smartest play here.